CNS Drug Discoveries: Sleep Disorders Chapter

Table of Contents

INSOMNIA

• EXECUTIVE SUMMARY
• THE FACTS
  • What is insomnia and why are we interested in it?
• PATIENT STATISTICS
  • Summary of insomnia patient population in top 5 European countries
• PATIENT MODEL
  • The addressable insomnia market will have a CAGR 2005-2012 = 5.9%
    • Patient population and sub-types of insomnia
    • Summary of patient population (for top seven countries) forecasts
• DRUG GROWTH DRIVERS
• DRUG GROWTH RISKS/DAMPNERS

GLOBAL INSOMNIA MARKET

• Global CNS Market (US$68.7 billion)
• GLOBAL SALES SPLIT
  • US market
    • Insomnia US drugs sales split (2005A)
  • European market
    • Insomnia European drugs sales split (2005A)
  • Japanese market
    • Insomnia Japanese drugs sales split (2005A)
  • The major players
    • Market share of insomnia players by sales (Dec 2005A)
  • Players and Products in 2005
  • Players and Products in 2012
    • Market share of insomnia players by sales (Dec 2012E)
• CURRENT TREATMENTS
  • Leading Brands
    • Comparison of Leading Brands
  • Current Products Patent Exposure
    • Patent exposure of leading brands
• ANALYSIS OF LEADING BRANDS
  • GABA-A Receptor Agonists
  • Melatonin Receptor Agonist
• GABA-A Receptor Agonists
  • Ambien/Stilnox/Myslee and Ambien CR (sanofi-aventis)
  • Lunesta (Sepracor)
  • Sonata (King Pharmaceuticals)
• Melatonin Receptor Agonist
  • Rozerem (Takeda)
    • Distribution of ML-1 and ML-2 receptors
• GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 - 2012
  • Sales Forecasts of Current Leading Insomnia Drugs (US$ million)
  • Model assumptions
• NEW DRUGS IN R&D
  • Drugs in Development to Treat Insomnia
• ANALYSIS OF PHASE III DRUGS
  • Drugs in Phase III Development to Treat Insomnia
  • GABA-A Receptor Agonists
  • Histamine Receptor Antagonist
  • 5-HT2A Receptor Antagonist
  • Melatonin Receptor Agonist
  • indiplon (Neurocrine Biosciences)
  • gaboxadol (Lundbeck)
  • Silenor (Somaxon)
  • Eplivanserin (sanofi-aventis)
    • Effect of eplivanserin on sleep parameters in Phase IIb trial
  • VEC-162 (Vanda Pharmaceuticals)
    • Efficacy of VEC-162 in transient insomnia trials
• GLOBAL SALES FORECASTS OF PHASE III INSOMNIA DRUGS 2006 - 2012
  • Sales Forecasts of Phase III Developmental Insomnia Drugs
  • Model assumptions
• ANALYSIS OF PHASE II DRUGS
  • New Drugs in Early Clinical Development to Treat Insomnia
  • 5-HT2A Receptor Antagonists
  • GABA-A Receptor Modulator
  • Melatonin Analogue
• 5-HT2A RECEPTOR ANTAGONISTS
  • M100907 (sanofi-aventis)
  • Pruvanserin (Eli Lilly)
• GABA-A MODULATORS
  • NG2-73 (Neurogen)
• MELATONIN ANALOGUE
  • PD-6735 (Phase II Discovery)
• GLOBAL SALES FORECASTS OF PHASE II INSOMNIA DRUGS 2006 - 2012
  • Sales Forecasts of Insomnia Drugs in Phase III
  • Model assumptions
    • CR Analysis of Insomnia Agents Approved by 2012 - Based on Drug Class
• COMPETITOR RATIO ANALYSIS - COMPANIES
  • CR Analysis of Insomnia Agents Approved by 2012 - Based on Company
  • WINNERS & LOSERS
    • Summary of Key Companies and Drugs in the Insomnia Market by 2012
  • Winners
  • Losers
• DISCONTINUATION OF DRUGS
• INSOMNIA APPENDIX 1
  • Analysis of clinical trial data
• INSOMNIA APPENDIX 2
  • Phase transition probability
    • Probability of launch
• INSOMNIA APPENDIX 3
  • Patient Model
    • Summary of US Insomnia Patient Population Forecasts
    • Summary of Europe (Top 5) Insomnia Patient Population Forecasts
    • Summary of Japan Insomnia Patient Population Forecasts
• INSOMNIA APPENDIX 4
  • Global Drug Sales 2005-2012 (US$ million)
• INSOMNIA APPENDIX 5
  • Competitor Ratio Analysis Criteria
    • Key insomnia drugs due to be launched by 2012
• INSOMNIA GLOSSARY
• INSOMNIA REFERENCES
• Acronyms